192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC. (Q53157920)
Jump to navigation
Jump to search
scientific article published on 15 April 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC. |
scientific article published on 15 April 2016 |
Statements
192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC. (English)
T Mok
P Schmid
O Arén
O Arrieta
M Gottfried
A R Jazieh
R Ramlau
K Timcheva
C Martin
S McIntosh
15 April 2016
11
4 Suppl
S140-1